Published in J Histochem Cytochem on July 11, 2007
BRCA1 immunohistochemistry in a molecularly characterized cohort of ovarian high-grade serous carcinomas. Am J Surg Pathol (2013) 0.92
Clinicopathological study of male breast carcinoma: 24 years of experience. Ann Saudi Med (2009) 0.92
The performance of BRCA1 immunohistochemistry for detecting germline, somatic, and epigenetic BRCA1 loss in high-grade serous ovarian cancer. Ann Oncol (2014) 0.78
Detecting BRCA2 protein truncation in tissue biopsies to identify breast cancers that arise in BRCA2 gene mutation carriers. J Clin Oncol (2009) 0.78
Identification of novel BRCA founder mutations in Middle Eastern breast cancer patients using capture and Sanger sequencing analysis. Int J Cancer (2016) 0.75
A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem (1976) 903.81
Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology (1991) 30.87
Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet (1998) 15.09
Mutation nomenclature extensions and suggestions to describe complex mutations: a discussion. Hum Mutat (2000) 13.25
Breast and ovarian cancer incidence in BRCA1-mutation carriers. Breast Cancer Linkage Consortium. Am J Hum Genet (1995) 9.06
Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst (2003) 8.48
Association of BRCA1 with Rad51 in mitotic and meiotic cells. Cell (1997) 8.28
Cancer risks in BRCA2 mutation carriers. J Natl Cancer Inst (1999) 8.15
Cancer Incidence in BRCA1 mutation carriers. J Natl Cancer Inst (2002) 6.58
The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. J Clin Oncol (2002) 6.16
Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. Am J Hum Genet (1998) 5.95
American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. J Clin Oncol (2003) 5.69
Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA (2006) 5.51
Conformation-sensitive gel electrophoresis for rapid detection of single-base differences in double-stranded PCR products and DNA fragments: evidence for solvent-induced bends in DNA heteroduplexes. Proc Natl Acad Sci U S A (1993) 5.47
Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. J Natl Cancer Inst (2002) 3.65
Aberrant subcellular localization of BRCA1 in breast cancer. Science (1995) 3.61
BRCA1 and BRCA2 and the genetics of breast and ovarian cancer. Hum Mol Genet (2001) 2.98
p53 mutations in BRCA1-associated familial breast cancer. Lancet (1997) 2.69
Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. J Clin Oncol (1998) 2.55
Cancer risks for male carriers of germline mutations in BRCA1 or BRCA2: a review of the literature. J Clin Oncol (2004) 2.25
The BRCA2 gene product functionally interacts with p53 and RAD51. Proc Natl Acad Sci U S A (1998) 1.97
Extraction and analysis of diagnostically useful proteins from formalin-fixed, paraffin-embedded tissue sections. J Histochem Cytochem (1998) 1.89
Location of BRCA1 in human breast and ovarian cancer cells. Science (1996) 1.88
Differential subcellular localization, expression and biological toxicity of BRCA1 and the splice variant BRCA1-delta11b. Oncogene (1997) 1.78
BRCA1 and BRCA2 founder mutations and the risk of colorectal cancer. J Natl Cancer Inst (2004) 1.76
Truncated BRCA2 is cytoplasmic: implications for cancer-linked mutations. Proc Natl Acad Sci U S A (1999) 1.54
The R71G BRCA1 is a founder Spanish mutation and leads to aberrant splicing of the transcript. Hum Mutat (2001) 1.36
Cytoplasmic mislocalization of BRCA1 caused by cancer-associated mutations in the BRCT domain. Exp Cell Res (2004) 1.29
Expression of DNA double-strand break repair proteins ATM and BRCA1 predicts survival in colorectal cancer. Clin Cancer Res (2006) 1.08
BRCA1 and BRCA2 mutation frequency in women evaluated in a breast cancer risk evaluation clinic. J Clin Oncol (2002) 1.06
Regulation of BRCA1, BRCA2 and BARD1 intracellular trafficking. Bioessays (2005) 1.05
Immunohistochemical expression of DNA repair proteins in familial breast cancer differentiate BRCA2-associated tumors. J Clin Oncol (2005) 1.05
BRCA1 gene expression in breast cancer: a correlative study between real-time RT-PCR and immunohistochemistry. J Histochem Cytochem (2005) 0.97
Immunohistochemistry identifies carriers of mismatch repair gene defects causing hereditary nonpolyposis colorectal cancer. J Clin Oncol (2005) 0.93
BRCA1 is localized in cytoplasmic tube-like invaginations in the nucleus. Nat Genet (1997) 0.92
The usefulness of antibodies to the BRCA1 protein in detecting the mutated BRCA1 gene. An immunohistochemical study. J Clin Pathol (2001) 0.91
Screening of BRCA1 mutation using immunohistochemical staining with C-terminal and N-terminal antibodies in familial ovarian cancers. Jpn J Cancer Res (2000) 0.84
Re: Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst (2004) 0.82
Immunohistochemical detection of a germline BRCA1 mutation in a breast and ovarian cancer family. Breast (2000) 0.76
Screening for a BRCA2 rearrangement in high-risk breast/ovarian cancer families: evidence for a founder effect and analysis of the associated phenotypes. J Clin Oncol (2007) 1.80
A guide for functional analysis of BRCA1 variants of uncertain significance. Hum Mutat (2012) 1.34
A randomised controlled phase II trial of pre-operative celecoxib treatment reveals anti-tumour transcriptional response in primary breast cancer. Breast Cancer Res (2013) 0.92
BRCA1 c.4987-3C>G is a pathogenic mutation. Breast Cancer Res Treat (2011) 0.75